HOOKIPA Pharma logo

HOOKIPA PharmaNASDAQ: HOOK

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 April 2019

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$34.84 M
-84%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector
-76%vs. 3y high
26%vs. sector
-95%vs. 3y high
18%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:19:11 GMT
$2.89+$0.05(+1.76%)

Dividend

No data over the past 3 years
$4.70 M$5.01 M
$4.70 M-$13.84 M

Analysts recommendations

Institutional Ownership

HOOK Latest News

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
globenewswire.com24 September 2024 Sentiment: POSITIVE

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
zacks.com02 September 2024 Sentiment: POSITIVE

The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

HOOKIPA Pharma Announces Board of Directors Changes
globenewswire.com30 August 2024 Sentiment: POSITIVE

NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com08 August 2024 Sentiment: POSITIVE

New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
globenewswire.com22 July 2024 Sentiment: POSITIVE

NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice President and Chief Financial Officer, effective July 22, 2024. They will both retain their positions on the Board of Directors (“Board”).

HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
globenewswire.com01 July 2024 Sentiment: POSITIVE

NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
globenewswire.com30 May 2024 Sentiment: POSITIVE

NEW YORK and VIENNA, May 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA or the Company), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of HOOKIPA's Executive Team will host an investor call on June 4, 2024, at 4:15 p.m. ET. Complete details and registration information are included below. The call will detail the Company's Phase 2 clinical data of HB-200 in combination with pembrolizumab for the treatment of human papillomavirus 16 positive head and neck cancer, including preliminary progression-free survival and overall survival data for patients with CPS ≥20.

HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
globenewswire.com23 May 2024 Sentiment: POSITIVE

NEW YORK and VIENNA, May 23, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers. The data were published in the Company's abstract for the ASCO 2024 Annual Meeting and support the Company's pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab in the first line setting.

HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research22 March 2024 Sentiment: POSITIVE

HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
Zacks Investment Research02 February 2024 Sentiment: POSITIVE

HOOKIPA Pharma Inc. (HOOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What type of business is HOOKIPA Pharma?

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

What sector is HOOKIPA Pharma in?

HOOKIPA Pharma is in the Healthcare sector

What industry is HOOKIPA Pharma in?

HOOKIPA Pharma is in the Biotechnology industry

What country is HOOKIPA Pharma from?

HOOKIPA Pharma is headquartered in United States

When did HOOKIPA Pharma go public?

HOOKIPA Pharma initial public offering (IPO) was on 18 April 2019

What is HOOKIPA Pharma website?

https://www.hookipapharma.com

Is HOOKIPA Pharma in the S&P 500?

No, HOOKIPA Pharma is not included in the S&P 500 index

Is HOOKIPA Pharma in the NASDAQ 100?

No, HOOKIPA Pharma is not included in the NASDAQ 100 index

Is HOOKIPA Pharma in the Dow Jones?

No, HOOKIPA Pharma is not included in the Dow Jones index

When was HOOKIPA Pharma the previous earnings report?

No data

When does HOOKIPA Pharma earnings report?

The next expected earnings date for HOOKIPA Pharma is 21 March 2025